Investigation of diagnostic and prognostic markers of severe cutaneous adverse drug reactions

严重皮肤药物不良反应诊断和预后标志物的研究

• 批准号: 23791243
• 负责人: MURATA Jyunko
• 金额: $ 2.66万
• 依托单位: Hokkaido University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23791243/
• 关键词: 皮膚炎症; 再生学; 重症薬疹; 中毒性表皮壊死症; Stevens-Johnson症候群; 早期診断マーカー; 可溶性FasL; グラニュライシン; 薬剤過敏症症候群

Severe cutaneous adverse drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) are life-threating diseases.In this project, we investigated to identify diagnostic and prognostic markers using patients’ PBMCs. Patients’ PBMCs were stimulated with causative drugs and mRNA and proteins were collected. These mRNA and proteins profiles were compared to those of non-severe cutaneous adverse drug reactions (maculopapular tyoe).We identified sFasL and granulysin are the markers.

严重的皮肤药物不良反应（Stevens-Johnson综合征和中毒性表皮坏死松解症）是危及生命的疾病，在本项目中，我们研究了使用患者的PBMC来确定诊断和预后标志物。用致病药物刺激患者的PBMC，收集mRNA和蛋白质。将这些mRNA和蛋白质谱与非严重皮肤药物不良反应（斑丘疹性Tyoe）的mRNA和蛋白质谱进行比较，我们确定sFasL和颗粒溶解素是标记物。